NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
Clinical Trials
10 trialsNCT06060704 2023-10-11
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT06039202 2023-09-15
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd
Phase 2 Unknown
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05004831 2022-08-18
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
Sun Yat-sen University
Phase 2 Unknown
NCT04683965 2022-08-02
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05266820 2022-03-18
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03762161 2022-03-10
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT05077839 2021-10-25
TOBACO
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04627961 2020-11-13
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma
National University Hospital, Singapore
Phase 2 Unknown